Samar S. M. Elsheikh

Samar S. M. Elsheikh

Auto-generated profile, based on publicly available information

Samar S. M. Elsheikh

Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Canada

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 January 2020 in Scientific Reports
Verified
Journal Article
Open access
PDF file
SESamar S. M. Elsheikh
Samar S. M. Elsheikh
Emile R. ChimusaEmile R. Chimusa
Emile R. Chimusa
NMNicola J. Mulder
Nicola J. Mulder
ACAlessandro Crimi
Alessandro Crimi
Variations in the human genome have been found to be an essential factor that affects susceptibility to Alzheimer’s disease. Genome-wide association studies (GWAS) have identified genetic loci that significantly contribute to the risk of Alzheimers. The availability of genetic data, coupled with brain imaging technologies have opened the door for further discoveries, by using data integration methodologies and new study designs. Although methods have been proposed for integrating image characteristics and genetic information for studying Alzheimers, the measurement of disease is often taken at a single time point, therefore, not allowing the disease progression to be taken into consideration. In longitudinal settings, we analyzed neuroimaging and single nucleotide polymorphism datasets obtained from the Alzheimer’s Disease Neuroimaging Initiative for three clinical stages of the disease, including healthy control, early mild cognitive impairment and Alzheimer’s disease subjects. We conducted a GWAS regressing the absolute change of global connectivity metrics on the genetic variants, and used the GWAS summary statistics to compute the gene and pathway scores. We observed significant associations between the change in structural brain connectivity defined by tractography and genes, which have previously been reported to biologically manipulate the risk and progression of certain neurodegenerative disorders, including Alzheimer’s disease.

26 January 2019
Verified
Book Chapter
Open access
PDF file
SESamar S. M. Elsheikh
Samar S. M. Elsheikh
Spyridon BakasSpyridon Bakas
Spyridon Bakas
NMNicola J. Mulder
Nicola J. Mulder
Emile R. ChimusaEmile R. Chimusa
Emile R. Chimusa
CDChristos Davatzikos
Christos Davatzikos
ACAlessandro Crimi
Alessandro Crimi
Glioblastoma is the most aggressive malignant primary brain tumor with a poor prognosis. Glioblastoma heterogeneous neuroimaging, pathologic, and molecular features provide opportunities for subclassification, prognostication, and the development of targeted therapies. Magnetic resonance imaging has the capability of quantifying specific phenotypic imaging features of these tumors. Additional insight into disease mechanism can be gained by exploring genetics foundations. Here, we use the gene expressions to evaluate the associations with various quantitative imaging phenomic features extracted from magnetic resonance imaging. We highlight a novel correlation by carrying out multi-stage genome-wide association tests at the gene-level through a non-parametric correlation framework that allows testing multiple hypotheses about the integrated relationship of imaging phenotype-genotype more efficiently and less expensive computationally. Our result showed several novel genes previously associated with glioblastoma and other types of cancers, as the LRRC46 (chromosome 17), EPGN (chromosome 4) and TUBA1C (chromosome 12), all associated with our radiographic tumor features.

24 June 2017 in Bioinformatics
Verified
Journal Article
Closed access
PDF file
JMJacquiline W Mugo
Jacquiline W Mugo
EGEphifania Geza
Ephifania Geza
JDJoel Defo
Joel Defo
SESamar S M Elsheikh
Samar S M Elsheikh
GMGaston Kuzamunu Mazandu
Gaston Kuzamunu Mazandu
Emile R. ChimusaEmile R. Chimusa
Emile R. Chimusa
Recent technological advances in high-throughput sequencing and genotyping have facilitated an improved understanding of genomic structure and disease-associated genetic factors. In this context, simulation models can play a critical role in revealing various evolutionary and demographic effects on genomic variation, enabling researchers to assess existing and design novel analytical approaches. Although various simulation frameworks have been suggested, they do not account for natural selection in admixture processes. Most are tailored to a single chromosome or a genomic region, very few capture large-scale genomic data, and most are not accessible for genomic communities. Here we develop a multi-scenario genome-wide medical population genetics simulation framework called ‘FractalSIM’. FractalSIM has the capability to accurately mimic and generate genome-wide data under various genetic models on genetic diversity, genomic variation affecting diseases and DNA sequence patterns of admixed and/or homogeneous populations. Moreover, the framework accounts for natural selection in both homogeneous and admixture processes. The outputs of FractalSIM have been assessed using popular tools, and the results demonstrated its capability to accurately mimic real scenarios. They can be used to evaluate the performance of a range of genomic tools from ancestry inference to genome-wide association studies. The FractalSIM package is available at http://www.cbio.uct.ac.za/FractalSIM. Supplementary data are available at Bioinformatics online.

5 October 2023 in The Canadian Journal of Psychiatry
Verified
Journal Article
Open access
FIFarhana Islam
Farhana Islam
LMLeen Magarbeh
Leen Magarbeh
SESamar S. M. Elsheikh
Samar S. M. Elsheikh
SKStefan Kloiber
Stefan Kloiber
CECaroline W. Espinola
Caroline W. Espinola
DMDaniel Mueller
Daniel Mueller
Objectives: Treatment-emergent sexual dysfunction is frequently reported by individuals with major depressive disorder (MDD) on antidepressants, which negatively impacts treatment adherence and efficacy. We investigated the association of polymorphisms in pharmacokinetic genes encoding cytochrome-P450 drug-metabolizing enzymes, CYP2C19 and CYP2D6, and the transmembrane efflux pump, P-glycoprotein (i.e., ABCB1), on treatment-emergent changes in sexual function (SF) and sexual satisfaction (SS) in the Canadian Biomarker Integration Network in Depression 1 (CAN-BIND-1) sample. Methods: A total of 178 adults with MDD received treatment with escitalopram (ESC) from weeks 0–8 (Phase I). At week 8, nonresponders were augmented with aripiprazole (ARI) (i.e., ESC + ARI, n = 91), while responders continued ESC (i.e., ESC-Only, n = 80) from weeks 8–16 (Phase II). SF and SS were evaluated using the sex effects (SexFX) scale at weeks 0, 8, and 16. We assessed the primary outcomes, SF and SS change for weeks 0–8 and 8–16, using repeated measures mixed-effects models. Results: In ESC-Only, CYP2C19 intermediate metabolizer (IM) + poor metabolizers (PMs) showed treatment-related improvements in sexual arousal, a subdomain of SF, from weeks 8–16, relative to CYP2C19 normal metabolizers (NMs) who showed a decline, F(2,54) = 8.00, p < 0.001, q = 0.048. Specifically, CYP2C19 IM + PMs reported less difficulty with having and sustaining vaginal lubrication in females and erection in males, compared to NMs. Furthermore, ESC-Only females with higher concentrations of ESC metabolite, S-desmethylcitalopram (S-DCT), and S-DCT/ESC ratio in serum demonstrated more decline in SF ( r = −0.42, p = 0.004, q = 0.034) and SS ( r = −0.43, p = 0.003, q = 0.034), respectively, which was not observed in males. ESC-Only females also demonstrated a trend for a correlation between S-DCT and sexual arousal change in the same direction ( r = −0.39, p = 0.009, q = 0.052). Conclusions: CYP2C19 metabolizer phenotypes may be influencing changes in sexual arousal related to ESC monotherapy. Thus, preemptive genotyping of CYP2C19 may help to guide selection of treatment that circumvents selective serotonin reuptake inhibitor-related sexual dysfunction thereby improving outcomes for patients. Additionally, further research is warranted to clarify the role of S-DCT in the mechanisms underlying ESC-related changes in SF and SS. This CAN-BIND-1 study was registered on clinicaltrials.gov (Identifier: NCT01655706) on 27 July 2012.

1 April 2018
Verified
Conference Paper
Closed access
SES. Elsheikh
S. Elsheikh
ECE. R. Chimusa
E. R. Chimusa
NMN. Mulder
N. Mulder
ACA. Crimi
A. Crimi
To better understand brain network disruption in Alzheimer disease (AD), advanced descriptors from genetics and neuroimaging can be useful. Combining those can help to shed new lights on neurodegeneration related to AD, since predicting brain changes is critically important for early treatment. We investigate correlation between global brain metrics changes and known gene biomarkers for AD. In practice, we construct connectivity networks using whole-brain tractography and examine the longitudinal changes. In a case-control setting, we compute the difference in time of global metrics of integration and segregation. Then, we observe that these longitudinal changes in metrics are correlated to the gene expression of known genetic biomarkers, such as the APOE and SPON1 genes, showing the relevance of these genes also in the pace of neurodegenerations.

29 March 2025 in The Canadian Journal of Psychiatry
Verified
Journal Article
Closed access
LMLeen Magarbeh
Leen Magarbeh
SESamar S. M. Elsheikh
Samar S. M. Elsheikh
FIFarhana Islam
Farhana Islam
VMVictoria S. Marshe
Victoria S. Marshe
XMXiaoyu Men
Xiaoyu Men
DMDaniel Mueller
Daniel Mueller
Objective: The genetic architecture of antidepressant response is poorly understood. This study investigated whether polygenic risk scores (PRSs) for major psychiatric disorders and a personality trait (neuroticism) are associated with antidepressant treatment outcomes. Methods: We analysed 148 participants with major depressive disorder (MDD) from the Canadian Biomarker Integration Network for Depression-1 (CAN-BIND-1) cohort. Participants initially received escitalopram (ESC) monotherapy for 8 weeks. Nonresponders at week 8 received augmentation with aripiprazole (ARI), while responders continued ESC until week 16. Primary outcomes were remission status and symptom improvement measured at weeks 8 and 16. At week 16, post-hoc stratified analyses were performed by treatment arm (ESC-only vs. ESC + ARI). Eleven PRSs derived from genome-wide association studies of psychiatric disorders (e.g., MDD and post-traumatic stress syndrome (PTSD)) and neuroticism, were analysed for associations with these outcomes using logistic and linear regression models. Results: At week 8, a higher PRS for PTSD was nominally associated with a lower probability of remission (odds ratio (OR) = 0.08 [0.014–0.42], empirical p -value = 0.017) and reduced symptom improvement (beta (standard error) = −29.15 (9.76), empirical p -value = 0.019). Similarly, a higher PRS for MDD was nominally associated with decreased remission probability (OR = 0.38 [0.18–0.78], empirical p -value = 0.044). However, none of the results survived multiple testing corrections. At week 16, the stratified analysis for the ESC-only group revealed that a higher PRS for MDD was associated with increased remission probability (empirical p- value = 0.034) and greater symptom improvement (empirical p -value = 0.02). In contrast, higher PRSs for schizophrenia (empirical p -value = 0.013) and attention-deficit hyperactivity disorder (empirical p -value = 0.032) were associated with lower symptom improvement. No significant associations were observed in the ESC + ARI group. Conclusions: These findings suggest that PRSs may influence treatment outcomes, particularly in ESC monotherapy. Replication in larger studies is needed to validate these observations.